Citigroup Downgrades Haemonetics to Neutral, Raises Price Target to $88

Benzinga · 3d ago
Citigroup analyst Joanne Wuensch downgrades Haemonetics (NYSE:HAE) from Buy to Neutral and raises the price target from $77 to $88.